Werewolf Therapeutics, Inc. · NASDAQ:HOWL
ANSBERT GADICKE reported a 5.40% stake in Werewolf Therapeutics, Inc. (Schedule 13D/A)
Event May 1, 2026 · Filed May 5, 2026
ANSBERT GADICKE reported a 5.40% stake in Werewolf Therapeutics, Inc., 2,608,501 shares, with active intent on May 1, 2026. Filed May 5, 2026 (Schedule 13D/A).
- Stake
- 5.40%
- Shares
- 2,608,501
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| MPM BioVentures 2014, L.P. | 2.30% | 1,131,359 |
| MPM BioVentures 2014 (B), L.P. | 0.20% | 75,458 |
| MPM Asset Management Investors BV2014 LLC | 0.10% | 38,939 |
| UBS Oncology Impact Fund L.P. | 1.90% | 936,031 |
| MPM BioVentures 2014 GP LLC | 2.50% | 1,206,817 |
| MPM BioVentures 2014 LLC | 2.60% | 1,245,756 |
| Oncology Impact Fund (Cayman) Management L.P. | 1.90% | 936,031 |
| MPM BioImpact LLC | 1.90% | 936,031 |
| ANSBERT GADICKE | 5.40% | 2,608,501 |
| LUKE EVNIN | 3.40% | 1,672,470 |
| Todd Foley | 2.60% | 1,245,756 |
| MPM ASSET MANAGEMENT LLC | 0.40% | 179,188 |
| MPM ONCOLOGY INNOVATIONS FUND LP | 0.50% | 247,526 |
| MPM Oncology Innovations Fund GP LLC | 0.50% | 247,526 |
Source
Related
- Werewolf Therapeutics, Inc.
- Ansbert Gadicke
- Werewolf Therapeutics, Inc. shareholders
- Schedule 13D/A · Ansbert Gadicke · May 12, 2026
- Schedule 13D/A · Ansbert Gadicke · Jan 16, 2026
- Schedule 13D/A · Ansbert Gadicke · Dec 29, 2025
- Schedule 13D/A · Ansbert Gadicke · Dec 3, 2025
- Schedule 13D/A · Ansbert Gadicke · Nov 17, 2025
- Schedule 13G · Moll Peter · Sep 21, 2026
- Form 4 · Luke Evnin · Jul 8, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jul 2, 2026
- Form 4 · Luke Evnin · Jun 29, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jun 26, 2026